SUO 2018: An Oncolytic Adenovirus, for BCG-unresponsive Non-muscle-invasive Bladder Cancer (NMIBC): 18-month Follow-up from a Multicenter Phase II Trial

Phoenix, Arizona ( Dr. Packiam presented his work from Mayo clinic, Rochester, on CG0070, an oncolytic adenovirus, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC): Final 18-month interim results from a multicenter phase 2 trial.

SUO 2018: Before and After Clinical CR from NAC

Phoenix, Arizona ( Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) or chemoradiation is the standard of care for urothelial carcinoma in patients with muscle-invasive bladder cancer (MIBC). Both cystectomy and chemoradiation carry potential short and long-term toxicity and quality of life implications. Sparing patients RC or chemoradiation after NAC without compromising oncologic outcomes would improve quality of life and decrease morbidity.

SUO 2018: Phase 2 Study of Pembrolizumab Monotherapy for High-Risk, Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG): Results from Keynote-057

Phoenix, Arizona ( Previous studies have demonstrated that constitutive PD-1 activation has been implicated in BCG resistance. While radical cystectomy is a standard option for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), it is associated with a high rate of perioperative morbidity and has a significant impact on patient quality of life.

SUO 2018: The Case for Neoadjuvant Immunotherapy

Phoenix, Arizona (  Dr. Necchi started his talk by pointing out that cisplatin-based neoadjuvant chemotherapy (NAC) is the standard of care (SoC) for muscle-invasive bladder cancer (MIBC) but the adherence to SoC is poor, and there are no good predictive biomarkers. Therefore, there is a need for other agents possibly immuno-oncology (IO) drugs. He highlighted the study by Forde et al. in NEJM in lung cancer patients, where neoadjuvant nivolumab was used and was associated with few side effects, did not delay surgery, and induced a significant pathological response in 45% of resected tumors.

SUO 2018: The Case for Adjuvant Immunotherapy

Phoenix, Arizona ( Dr. Steinberg began his talk by highlighting all the FDA approved checkpoint inhibitor therapies in metastatic urothelial cancer following cisplatin. The use of immune-oncology (IO) agents has revolutionized the management of patients with locally advanced, unresectable, and metastatic urothelial carcinoma. Antibodies directed against the checkpoints ‘programmed cell death 1’ (PD-1) and ‘programmed death ligand 1’ (PD-L1) were shown to induce rapid and durable responses in advanced urothelial in the salvage setting and for patients in the first line-setting who are cisplatin-ineligible.

SUO 2018: Preclinical Models in Bladder Cancer and Translational Research

Phoenix, Arizona ( At the Bladder Cancer Session II at SUO 2018, Dr. James M. McKiernan, Chairman of Urology and Director of Urologic Oncology at Columbia University, New York, NY, presented an overview of preclinical models in bladder cancer and translational research.

SUO 2018: Combination Chemotherapy-Immunotherapy for Bladder Cancer

Phoenix, Arizona ( Dr. William Tabayoyong, a Society of Urologic Oncology Fellow at MD Anderson Cancer Center wrapped up the 2018 annual meeting of the Society of Urologic Oncology by giving a research scholar’s update on his translational work looking at combination chemoimmunotherapy in patients with muscle invasive bladder cancer (MIBC).
Page 1 of 3

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.